Sandu Pharmaceuticals Limited has published a newspaper notice regarding the Second 100-Day Campaign 'Saksham Niveshak' for KYC updates and shareholder engagement, following SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. The company submitted the newspaper publication notice to the Bombay Stock Exchange on April 4, 2026, as part of its regulatory compliance under Regulation 30.

Campaign Details and Timeline

The Second 100-Day Campaign 'Saksham Niveshak' is an initiative by the Investor's Education and Protection Fund Authority (IEPFA) designed to facilitate direct payment of unclaimed dividends to eligible shareholders. The campaign focuses on shareholders whose dividends remain unclaimed, with particular emphasis on KYC updates and related compliance measures.

Registrar and Transfer Agent Information

Sandu Pharmaceuticals has appointed MUFG Intime India Private Limited as its Registrar and Transfer Agent to facilitate the campaign process. Shareholders with incomplete KYC records or unclaimed dividends are advised to contact the RTA promptly to complete necessary formalities.

Special Window for Physical Securities

The notice also highlights a special window available from February 5, 2026 to February 4, 2027 for transfer and dematerialization of physical securities. This facility covers transfer requests that were previously submitted but rejected, returned, or remained in process. Securities transferred under this special window will be credited only in demat mode and subject to a one-year lock-in period from the date of registration.

Compliance and Shareholder Action

The company emphasizes that dividends remaining unclaimed for seven consecutive years are liable to be transferred to the IEPFA along with corresponding shares. Shareholders are urged to take prompt action during the campaign period to safeguard their entitlements and ensure compliance with statutory requirements. The detailed circular and additional information are available on the company's website at https://sandu.in/circulars-to-investors/ .

Elixir Capital Limited has informed the stock exchanges about a SEBI settlement order affecting its subsidiary company under a regulatory scheme targeting algorithmic trading platform associations. The disclosure was made on March 20, 2026, pursuant to Regulation 30 of the SEBI Listing Regulations.

SEBI Settlement Order Details

The Securities and Exchange Board of India has issued a settlement order under the 'Settlement Scheme for Association with Certain Algo Platforms, 2025', which covers 111 stock brokers across the industry. Elixir Equities Private Limited, a subsidiary of Elixir Capital Limited, is among the entities covered under this scheme.

Nature of Alleged Violations

The settlement pertains to the subsidiary's alleged association with certain algorithmic platforms. According to the company's disclosure, these practices were viewed as violations of:

• Applicable SEBI circulars
• Provisions of the SEBI (Stock Brokers) Regulations, 1992

The regulatory action specifically targets practices related to algorithmic trading platforms that were deemed non-compliant with existing securities regulations.

Financial and Operational Impact

Elixir Capital has clarified that the settlement order does not directly relate to the listed entity itself, but only to its subsidiary. The company has assessed the impact as follows:

Company Response and Compliance Commitment

The company has emphasized its commitment to maintaining high compliance standards. Elixir Capital stated that both the parent company and its subsidiary will take necessary steps to address the regulatory concerns raised in the settlement order.

The disclosure was signed by Radhika Mehta, Whole-Time Director of Elixir Capital Limited, and submitted to BSE Limited for record-keeping purposes. The company noted that while the settlement order was dated March 17, 2026, no formal communication was received directly from SEBI, and the order was acknowledged based on its publication on the regulator's official website.